collaboration

OneOncology, a network comprising community oncology practices across the US, will bring its patient data to the research-focused partnership.

The kit, which received EUA from the FDA in May, will be used to test clinical samples from patients at D-HH member hospitals.

The company developed the test with labs at Emory University, Stanford University, the University of Cincinnati, and the University Health Network in Toronto.

The companies are validating the Genedrive 96 Sars-CoV-2 kit using saliva samples extracted with Beckman Coulter's RNAdvance viral extraction chemistry

The viral assay, developed with Sentinel Diagnostics, improves the ability to monitor viral loads in critical organ transplant populations for the clinical management of infection.

The governors of the six states are collaborating with the Rockefeller Foundation to expand access to point-of-care antigen testing for SARS-CoV-2.

Pathnova, will further develop and commercialize Todos' tests in Singapore, while Todos will assist Pathnova to commercialize its nasopharyngeal cancer tests.

The company is employing Guardant360 in a Phase III trial assessing the efficacy of the drug both in a larger population and in women who test positive for ESR1 mutations.

MaviDx will develop, validate, secure regulatory approvals for, and commercialize its SARS-CoV-2 and other infectious disease tests, including for influenza, on Veracyte's nCounter system.

The assay is designed to detect immunoglobulin G and M antibodies against SARS-CoV-2 in human blood, plasma, and serum, with results provided in 15 minutes.